ArticleScientific reports2025
CX3CL1 promotes M1 macrophage polarization and osteoclast differentiation via NSUN5-mediated m5C modification.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- RNA cytosine modifications regulates musculoskeletal disorders.Molecular biology reports · 2026Review
- Heat Stress Modulates WDR5-Mediated H3K4me3 Modification to Induce Melanogenesis via Activating CX3CL1/CX3CR1 Axis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The Role of NSUN Family Genes in m5C Methylation and Diseases.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone homeostasis refers to a dynamic equilibrium maintained between osteogenesis and osteoclastic bone resorption within the skeletal system. CX3CL1 (Fractalkine) is a chemokine that plays a significant regulatory role in bone homeostasis. This study aimed to investigate the mechanisms by which CX3CL1 regulates bone homeostasis. The expression of CX3CL1 in LPS-stimulated and RANKL-stimulated macrophages was examined using qPCR and Western blotting. Functional studies employed shRNA-mediated knockdown and overexpression of CX3CL1/NSUN5, followed by analysis of pro-inflammatory factor levels(IL-1β, IL-6, iNOS, and TNF-α), M1/M2 markers (CD86/CD206), osteoclast activity (TRAP staining, CTX-1 level), and key osteoclastogenic factors (NFATc1, c-Fos). Potential mechanisms were validated using Methylated RNA Immunoprecipitation (MeRIP), RNA Immunoprecipitation (RIP), and Dual-Luciferase Reporter Assay experiments. An ovariectomy (OVX)-induced osteoporosis mouse model was used for in vivo validation. Results showed that CX3CL1 was significantly upregulated in LPS- and RANKL-stimulated RAW 264.7 cells. Knockdown of CX3CL1 inhibited macrophage M1 polarization and osteoclast differentiation. NSUN5 interacted with CX3CL1 and suppressed its stability by promoting the m5C modification of CX3CL1 mRNA. Additionally, Overexpression of CX3CL1 reversed the inhibitory effect of NSUN5 overexpression on macrophage M1 polarization and osteoclast differentiation. In OVX mice, NSUN5 overexpression preserved bone mass (increased BV/TV, reduced Tb.Sp), while CX3CL1 co-expression abolished this protection. In conclusion, CX3CL1 accelerates M1 macrophage polarization and promotes osteoclast differentiation, mechanistically regulated by m5C modification mediated by NSUN5. This study provides novel therapeutic strategies and targets for maintaining bone homeostasis and preventing and treating bone-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.